| 000 | 01861 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250515202451.0 | ||
| 264 | 0 | _c20101216 | |
| 008 | 201012s 0 0 eng d | ||
| 022 | _a1536-4844 | ||
| 024 | 7 |
_a10.1002/ibd.21194 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aIto, Hiroaki | |
| 245 | 0 | 0 |
_aDirect comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study. _h[electronic resource] |
| 260 |
_bInflammatory bowel diseases _cSep 2010 |
||
| 300 |
_a1575-82 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents, Non-Steroidal _xchemistry |
| 650 | 0 | 4 | _aChemistry, Pharmaceutical |
| 650 | 0 | 4 |
_aColitis, Ulcerative _xdrug therapy |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aHydrogen-Ion Concentration |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMesalamine _xchemistry |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPharmaceutical Preparations _xadministration & dosage |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aIida, Mitsuo | |
| 700 | 1 | _aMatsumoto, Takayuki | |
| 700 | 1 | _aSuzuki, Yasuo | |
| 700 | 1 | _aAida, Yoshiyuki | |
| 700 | 1 | _aYoshida, Toyomitsu | |
| 700 | 1 | _aTakano, Yuichi | |
| 700 | 1 | _aHibi, Toshifumi | |
| 773 | 0 |
_tInflammatory bowel diseases _gvol. 16 _gno. 9 _gp. 1575-82 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/ibd.21194 _zAvailable from publisher's website |
| 999 |
_c19429274 _d19429274 |
||